CSI Market
Sign In | Register

Eloxx Pharmaceuticals Inc (ELOX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ELOX Annual Cash Flow →
A period-by-period view of cash flow from Eloxx Pharmaceuticals Inc to Mar 31 2023 helps clarify how Mar 31 2026's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Operating Activities
Income-3.75
Depreciation & amortization0.00
Amortization of Other Assets0.01
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.05
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-0.06
Deferred Rent-
Unrealized Gain Loss On Stock Rights-
Unrealized Gain Loss On Warrant Derivatives-
Noncash Or Part Noncash Acquisition Payables Assumed-
Non Cash Or Part Non Cash Acquisition Accrued Pay Roll-
Non Cash Or Part Non Cash Acquisition Accrued Expenses-
Non Cash Or Part Non Cash Acquisition Deferred Tax Liability-
Operating Lease Right Of Use Asset Amortization-
Amortization And Revaluation Of Discount In Respect To Convertible Loan-
Gain On Extinguishment Of Debt-
Gain On Extinguishment Of Paycheck Protection Program Debt-
Operating Lease Right Of Use Asset Amortization Expense-
Increase Decrease In License Fee Receivable-
Increase Decrease In Operating Lease Liabilities-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accrued Interest Receivable, Net0.02
Increase (Decrease) in Accounts Payable0.32
Increase (Decrease) in Accrued Liabilities-0.38
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.66
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-5.45
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Long-term Investments, Total0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.04
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net2.20
Proceeds From Government Grant-
Proceeds From Issuance Of Preferred Stock And Warrants Net-
Proceeds From Issuance Of Bridge Notes-
Debt Conversion Converted Instrument Amount-
Proceeds From Issuance Of Preferred Stock And Preference Stock Net-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations4.79
Noncash Acquisition Of Treasury Shares-
Non Cash Issuance Of Shares Upon Exercise Of Warrants-
Fair Value Of Warrants Issued In Connection With Long Term Debt-
Non Cash Final Payment On Debt Financing Obligation-
Non Cash Deferred Public Offering Costs In Accounts Payable And Accruals-
Proceeds From Advances From Collaboration Partners-
Proceeds From Advances From Collaboration Partner-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities7.03
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.45
Total Cash Flow1.58
4 historic quarters locked

Sign in to unlock the full Eloxx Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Eloxx Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-344964

Figures are derived from filed reports and may be restated. Historical data is subject to revision.